AstraZeneca PLC is hoping to claim a piece of the obesity market, believing its cardiovascular, renal and metabolism (CVRM) strength will be an advantage, despite being well behind rivals. The company announced a licensing deal with Eccogene (Shanghai) Co., Ltd for an oral glucagon-like peptide 1 (GLP-1) receptor agonist for the treatment of obesity, type 2 diabetes and other cardiometabolic conditions on 9 November, coinciding with its third quarter sales and earnings announcement.
AstraZeneca Moves Into Obesity With Eye On Combinations
The company licensed an oral GLP-1 agonist from Eccogene, hoping to capitalize on its heritage in cardiovascular disease. AstraZeneca also reported third quarter results.
More from Alimentary/Metabolic
More from Therapy Areas
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.